• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
South Africa Pharmaceuticals and Healthcare Report Q4 2012 - Product Image

South Africa Pharmaceuticals and Healthcare Report Q4 2012

  • Published: November 2012
  • Region: Africa, South Africa
  • 104 pages
  • Business Monitor International

FEATURED COMPANIES

  • Adcock Ingram
  • Cipla Medpro South Africa
  • Local Companies
  • Multinational Companies
  • Pfizer
  • Roche
  • MORE

BMI View:

The government drive to support local production and reduce the country’s reliance on imports, in addition to global epidemiological and demographic trends, are all positive factors contributing to long-term growth in the pharmaceutical market. However, deep segregation between private and public healthcare facilities continues to leave the vast majority of the population without medical care. BMI believes this will be rectified through the creation of the National Health Insurance scheme over the next decade, but in the meantime unemployment, lack of education and geographical inaccessibility to healthcare for the wider population will continue to hinder growth in the market.

Headline Expenditure Projections:

- Pharmaceuticals: ZAR27.19bn (US$3.74bn) in 2011 to ZAR29.61bn (US$3.61bn) in 2012;
+8.9% in local currency and -3.5% in US dollar terms.

- Healthcare: ZAR261.51bn (US$36.01bn) in 2011 to ZAR285.26bn (US$34.79bn) in 2012;
+9.1% in local currency terms and -3.4% in US dollar terms.

- Medical devices: ZAR11.43bn (US$1.57bn) in 2011 to ZAR12.19bn (US$1.49bn) in 2012;
+6.7% in local currency terms and -5.5% in US dollar READ MORE >

Executive Summary 7

SWOT Analysis 8

South Africa Pharmaceuticals And Healthcare Industry SWOT 8

South Africa Political SWOT 9

South Africa Economic SWOT 9

South Africa Business Environment SWOT 10

Pharmaceutical Risk/Reward Ratings 11
Table: Middle East And Africa Pharmaceutical Risk/Reward Ratings, Q412 11

Rewards 13

Risks 13

South Africa – Market Summary 15

Regulatory Regime 17
Table: Drug Classification System 18

SAHPRA 19

SAGMA 20

Pharmaceutical Advertising 21

Intellectual Property Environment 21

Counterfeit Activity 22

Pricing System 22
Table: Tiered Pharmaceutical Pricing System Is Better Than A Flat Fixed Mark-Up 23

Price Increases 24
Table: SEP Inflation, 2008-2011 24

Pricing Developments 24

Reimbursement System 25

Industry Developments 26

Epidemiology 26

HIV/AIDS 27

Tuberculosis 29

Healthcare Sector 30

National Health Insurance Scheme 31

Public Healthcare Reform 32

Private Healthcare Regulation 33

National Health Reference Price List 35

Government Health Insurance 35

Research & Development Sector 36

Clinical Trials 38

Vaccines 39

Traditional African Medicine 39

Medical Devices 40
Table: Customs Classification Of Medical Devices 42

Industry Forecast Scenario 44

Overall Market Forecast 44
Table: Pharmaceutical Sales Indicators 2008-2016 45

Key Growth Drivers – Industry 46
Table: Healthcare Expenditure Indicators 2008-2016 47
Table: Healthcare Governmental Indicators 2008-2016 48
Table: Healthcare Private Indicators 2008-2016 48

Key Growth Factors – Macroeconomic 49
Table: South Africa – Real GDP Growth (q-o-q SAAR) 49
Table: South Africa – Major Gold Expansion Projects 52
Table: South Africa – Economic Activity, 2011-2016 52

Prescription Drug Market Forecast 53
Table: Prescription Drug Sales Indicators 2008-2016 54

Patented Drug Market Forecast 54
Table: Patented Drug Market Indicators 2008-2016 55

Generic Drug Market Forecast 56
Table: Generic Drug Sales Indicators 2008-2016 58

OTC Medicine Market Forecast 58
Table: OTC Medicine Sales Indicators 2008-2016 60

Pharmaceutical Trade Forecast 60
Table: Exports and Imports Indicators 2008-2016 63

Medical Device Market Forecast 64
Table: Medical Devices Sales Indicators 2008-2016 65

Other Healthcare Data 66

Key Risks To our Forecast Scenario 66

Competitive Landscape 68

Pharmaceutical Industry 68

Pharmaceutical Sector Developments 69

Retail Pharmacy Sector 73

Company Profiles 74

Local Companies 74

Aspen Pharmacare 74

Adcock Ingram 77

Cipla Medpro South Africa 79

Multinational Companies 81

Sanofi 81

Pfizer 83

Roche 85

Ranbaxy 87

GlaxoSmithKline 89

Merck & Co 91

Novartis 93

Demographic Outlook 94
Table: Population By Age Group, 1990-2020 (‘000) 95
Table: South Africa’s Population By Age Group, 1990-2020 (% of total) 96
Table: Key Population Ratios, 1990-2020 97
Table: Rural/Urban Population Split, 1990-2020 97

Glossary 98

BMI Methodology 100

How We Generate Our Pharmaceutical Industry Forecasts 00

Pharmaceuticals Risk/Reward Ratings Methodology 01

Ratings Overview 01
Table: Pharmaceutical Business Environment Indicators 02

Weighting 03
Table: Weighting Of Components 03

Sources 03

Local Companies
Aspen Pharmacare
Adcock Ingram
Cipla Medpro South Africa
Multinational Companies
Sanofi
Pfizer
Roche
Ranbaxy
GlaxoSmithKline
Merck & Co
Novartis

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos